Literature DB >> 33259966

Successful hematopoietic stem cell transplantation in a 4-1BB deficient patient with EBV-induced lymphoproliferation.

Christine Wildermann1, Mohammed Alosaimi2, Sophie Liebenehm3, Eva-Maria Jacobsen3, Thomas F E Barth4, Peter Möller4, Klaus-Michael Debatin3, Ansgar Schulz3, Mehtap Sirin3, Ibraheem F Abosoudah5, Fowzan S Alkuraya6, Raif S Geha7, Manfred Hönig3.   

Abstract

Complete remission from recurrent EBV-positive lymphoma is not mandatory before HSCT to achieve long-term cure in a patient suffering from a recently described immunodeficiency affecting the T-cell coactivation molecule 4-1BB.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  4-1BB; Epstein Barr virus; HSCT; Recurrent lymphoproliferation

Mesh：

Substances：

Year:  2020        PMID： 33259966      PMCID： PMC8785803          DOI： 10.1016/j.clim.2020.108639

Source DB:  PubMed          Journal:  Clin Immunol        ISSN： 1521-6616            Impact factor:   3.969


  4 in total

1.  Immunodeficiency and EBV-induced lymphoproliferation caused by 4-1BB deficiency.

Authors:  Mohammed F Alosaimi; Manfred Hoenig; Faris Jaber; Craig D Platt; Jennifer Jones; Jacqueline Wallace; Klaus-Michael Debatin; Ansgar Schulz; Eva Jacobsen; Peter Möller; Hanan E Shamseldin; Ferdous Abdulwahab; Niema Ibrahim; Hosam Alardati; Faisal Almuhizi; Ibraheem F Abosoudah; Talal A Basha; Janet Chou; Fowzan S Alkuraya; Raif S Geha
Journal:  J Allergy Clin Immunol       Date:  2019-03-11       Impact factor: 10.793

2.  CD137 deficiency causes immune dysregulation with predisposition to lymphomagenesis.

Authors:  Ido Somekh; Marini Thian; David Medgyesi; Nesrin Gülez; Thomas Magg; Alejandro Gallón Duque; Tali Stauber; Atar Lev; Ferah Genel; Ekrem Unal; Amos J Simon; Yu Nee Lee; Artem Kalinichenko; Jasmin Dmytrus; Michael J Kraakman; Ginette Schiby; Meino Rohlfs; Jeffrey M Jacobson; Erdener Özer; Ömer Akcal; Raffaele Conca; Türkan Patiroglu; Musa Karakukcu; Alper Ozcan; Tala Shahin; Eliana Appella; Megumi Tatematsu; Catalina Martinez-Jaramillo; Ivan K Chinn; Jordan S Orange; Claudia Milena Trujillo-Vargas; José Luis Franco; Fabian Hauck; Raz Somech; Christoph Klein; Kaan Boztug
Journal:  Blood       Date:  2019-10-31       Impact factor: 22.113

Review 3.  Primary immunodeficiencies reveal the molecular requirements for effective host defense against EBV infection.

Authors:  Stuart G Tangye; Sylvain Latour
Journal:  Blood       Date:  2020-02-27       Impact factor: 22.113

4.  Concomitant PIK3CD and TNFRSF9 deficiencies cause chronic active Epstein-Barr virus infection of T cells.

Authors:  Rémy Rodriguez; Benjamin Fournier; Debora Jorge Cordeiro; Sarah Winter; Kazushi Izawa; Emmanuel Martin; David Boutboul; Christelle Lenoir; Sylvie Fraitag; Sven Kracker; Tania H Watts; Capucine Picard; Julie Bruneau; Isabelle Callebaut; Alain Fischer; Bénédicte Neven; Sylvain Latour
Journal:  J Exp Med       Date:  2019-09-19       Impact factor: 14.307
  4 in total
  3 in total

Review 1.  Novel Discoveries in Immune Dysregulation in Inborn Errors of Immunity.

Authors:  Anwen Ren; Wei Yin; Heather Miller; Lisa S Westerberg; Fabio Candotti; Chan-Sik Park; Pamela Lee; Quan Gong; Yan Chen; Chaohong Liu
Journal:  Front Immunol       Date:  2021-08-27       Impact factor: 7.561

2.  Compound heterozygous variants in OTULIN are associated with fulminant atypical late-onset ORAS.

Authors:  Catharina Schuetz; Pamela Fischer-Posovszky; Klaus-Michael Debatin; Julia Zinngrebe; Barbara Moepps; Thomas Monecke; Peter Gierschik; Ferdinand Schlichtig; Thomas F E Barth; Gudrun Strauß; Elena Boldrin; Carsten Posovszky; Ansgar Schulz; Ortraud Beringer; Eva Rieser; Eva-Maria Jacobsen; Myriam Ricarda Lorenz; Klaus Schwarz; Ulrich Pannicke; Henning Walczak; Dierk Niessing
Journal:  EMBO Mol Med       Date:  2022-02-16       Impact factor: 14.260

Review 3.  Co-Stimulatory Molecules during Immune Control of Epstein Barr Virus Infection.

Authors:  Christian Münz
Journal:  Biomolecules       Date:  2021-12-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.